Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIGMENT – PDE6A gene therapy for retinitis pigmentosa
2024-517924-20-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Sep 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2 trial of rAAV.hPDE6A in retinitis pigmentosa (RP), sponsored by University Hospital Tübingen. Planned start Sep 2024; status: authorised.
02
Drugs
rAAV.hPDE6A
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2024-517924-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517924-20-00.